---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-001690"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:02:44.536982+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Vistagen releases corporate presentation highlighting nose-to-brain neuroscience platform

## Summary
- Presentation dated January 2026 describes nose-to-brain neurocircuitry for CNS disorders.
- No financial data, pipeline updates, or milestones disclosed in the filing excerpt.
- VTGN common stock trades on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001628280-26-001690
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000162828026001690/0001628280-26-001690-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000162828026001690/vtgn-20260109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-001690
- JSON: https://secwatch.observer/filing/0001628280-26-001690.json
- Plain text: https://secwatch.observer/filing/0001628280-26-001690.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.